🇺🇸 FDA
Patent

US 11338029

Cancer vaccines targeting PRAME and uses thereof

granted A61KA61K2039/53A61K2039/55527

Quick answer

US patent 11338029 (Cancer vaccines targeting PRAME and uses thereof) held by Inovio Pharmaceuticals, Inc. expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inovio Pharmaceuticals, Inc.
Grant date
Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/53, A61K2039/55527, A61K2039/55533, A61K2039/55538